Therapeutics Daily

Therapeutics Daily


Schering Says Hepatitis Drug Matches Roche Medicine

Reuters Health - Jan. 14, 2008
NEW YORK (Reuters) - Schering-Plough Corp said on Monday that its Pegintron treatment for hepatitis C was just as effective as Roche Holding AG's rival Pegasys medicine in a large clinical trial, and fewer patients taking Pegintron relapsed after treatment.

Moreover, Schering-Plough said a lower-dose formulation of its injectable Pegintron -- a type of interferon that spurs the immune system to attack the liver-damaging hepatitis C virus -- was as effective as the standard dose of Pegintron.

Schering-Plough said the so-called IDEAL study was the first large formal clinical trial that compared the two medicines, both of ...